The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Levodopa and non-ergot dopaminergic agonists such as pramipexole are both recommended as the
first-line symptomatic treatment for early untreated Parkinson's disease (PD), previous
clinical trial indicated that initial pramipexole owns advantage over levodopa regarding
motor complications, on the contrary, less adverse effect like freezing and severe somnolence
favors initial treatment of levodopa. Thus, it remains controversial that initiation of which
medication will be better for those patients with early PD.
Parkinson's disease-related spatial covariance patter (PDRP) is a new biomarker which can
represent the network activity of brain and severity of PD. Based on the literatures and our
previous data, the investigators hypothesize that PDRP will be served as a biomarker to help
us evaluate and compare the effect of levodopa or pramipexole on the progression of PD, which
might be able to provide further evidence for clinicians to address the above critical issue.
Phase:
N/A
Details
Lead Sponsor:
Huashan Hospital
Collaborator:
Boehringer Ingelheim
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa Pramipexole